Bio2 Technologies received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold.
CLM is constructed from bioactive glass, a resorbable implantable material. Bio2 has successfully applied the proprietary CLM process technology to produce a rigid, osteoconductive material with an interconnected porous structure facilitating the ingrowth and remodeling of healthy bone.
Bio2 is focused on developing a number of CLM-constructed products designed for reconstructive surgery of the extremities.
More articles on devices:
Amedica's 2014 revenue to hit $22M to $24M — 6 things to know
Sonoma Orthopedic Products receives $12M in financing round
THINK Surgical's surgical system for THA receives FDA approval